Clinical Trial Update: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Onalespib in combination with AT7519 in patients with advanced, metastatic, or unresectable solid tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor
• Unresectable Solid Tumor

Drugs mentioned

• AT7519 (AT7519)
• Onalespib (onalespib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED